Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

Clinical Trials

Living with and learning about neuroendocrine tumors: A conversation with Dr. Jaydira Del Rivero

Jaydira Del Rivero, M.D., Assistant Research Physician in the Developmental Therapeutics Branch, studies neuroendocrine tumors – a rare group of malignant neoplasms that originates from neuroendocrine cells and affects almost any part of the body. In this Q&A, Dr. Del Rivero and a natural history trial participant discuss an ongoing neuroendocrine study and their experiences at NIH.

Clinical trial evaluates drug for treatment of neurofibromatosis type 1 and atypical neurofibromas

Up to half of the people with neurofibromatosis type 1 develop plexiform neurofibromas (PNs), tumors that grow along nerves. Over time, PNs may transform into atypical neurofibromas (ANFs) and then into cancerous tumors. Andrea Gross, M.D., Assistant Research Physician in the Pediatric Oncology Branch, is leading a study of a drug, abemaciclib, to treat ANFs in children.

Clinical trial compares interval dosing of two immune checkpoint inhibitors

William D. Figg Sr., Pharm.D., Deputy Chief of the Genitourinary Malignancies Branch, is leading CCR’s efforts in a multi-institution, international study comparing methods of dosing nivolumab and pembrolizumab. This study is intended for people who have advanced or metastatic cancer that has not been previously treated with an immune checkpoint inhibitor.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

All about the drive: A rare kidney cancer meets its match at NIH

On New Year’s Eve, 2020, Katie Coleman was diagnosed with a very rare form of advanced kidney cancer. She enrolled in a clinical trial led by a collaborative CCR team that gave her the opportunity to have surgery in hopes of removing her tumors.

Clinical trial researches drug combination with immunotherapy for mesothelioma

Mesothelioma is a rare, fast-growing cancer that forms in membranes that surround and protect the heart, lungs and abdomen. The cells of malignant mesothelioma express large amounts of mesothelin, a cancerous protein. Investigators are researching a mesothelin-targeting drug in combination with immunotherapy.

GPC3 expression in hepatocellular carcinoma

Clinical trial targets cell surface protein GPC3 to treat advanced hepatocellular carcinoma

Tim F. Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a study of advanced hepatocellular carcinoma, a common type of liver cancer with a poor prognosis. The research uses CAR T-cell therapy to target GPC3-positive tumor cells while avoiding healthy tissue.

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

New evidence suggests that adding the drug ibrutinib to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live. The findings come from a new analysis led by Louis M. Staudt, M.D., Ph.D., Chief of the Lymphoid Malignancies Branch, of a previous phase III clinical trial.

Clinical trial studies breast cancer drug abemaciclib as a therapy for Kaposi sarcoma

Kaposi sarcoma (KS) is a rare cancer that causes patches of abnormal tissue to develop in different regions of the body, and lesions in the lungs, liver, or digestive tract can be life-threatening. Investigators are studying abemaciclib, a drug used for people with breast cancer, to see if it can positively impact those with KS.

Clinical trial evaluates new combination therapy for virus-associated malignancies

Several viruses can cause cancer and less toxic and more effective treatments are urgently needed for these cancers. Kathryn A. Lurain, M.D., M.P.H., Assistant Research Physician in the HIV and AIDS Malignancy Branch, is leading a trial of a combination treatment for virus-associated malignancies.

Breadcrumb

Clinical Trials